» Articles » PMID: 1673424

Disposition of the Cephalosporin Cefepime in Normal and Renally Impaired Subjects

Overview
Specialty Pharmacology
Date 1991 Jan 1
PMID 1673424
Citations 17
Authors
Affiliations
Soon will be listed here.
Abstract

The metabolism and disposition of an iv-administered, 1000 mg (100 microCi) single dose of the 14C-labeled cephalosporin cefepime was studied in healthy and renally impaired male volunteers. The 14C-label was located in the methyl group of the N-methyl pyrrolidine (NMP) moiety at the 3'-position of cefepime. Concentrations of cefepime and its metabolites were determined in plasma and urine as a function of time after drug administration. Cefepime comprised 95 and 76% of the total plasma radioactivity in subjects with normal and impaired renal functions, respectively. The elimination half-life of cefepime was 2 hr in normal volunteers and increased to 4 and 12 hr in subjects with moderate and severe renal impairment, respectively. Steady-state volume of distribution was about 18 liters and was independent of the degree of renal impairment. Cefepime was primarily excreted unchanged in the urine of normal subjects, as 87.9% of the total recovered radioactivity. The major cefepime metabolites, NMP N-oxide, the 7-epimer of cefepime and NMP, constituted 6.8, 2.5, and less than 1% of the total radioactivity excreted in urine, respectively. As the severity of renal impairment increased, the proportion of radioactivity recovered in urine as cefepime decreased and that of NMP-N-oxide increased. Our results indicate that cefepime undergoes minimal metabolism and is excreted primarily as unchanged drug in urine in humans with normal kidney functions.

Citing Articles

Clinical Pharmacokinetics and Pharmacodynamics of Cefepime.

Pais G, Chang J, Barreto E, Stitt G, Downes K, Alshaer M Clin Pharmacokinet. 2022; 61(7):929-953.

PMID: 35764774 PMC: 9345683. DOI: 10.1007/s40262-022-01137-y.


Potential Antibiotics for the Treatment of Neonatal Sepsis Caused by Multidrug-Resistant Bacteria.

Darlow C, da Costa R, Ellis S, Franceschi F, Sharland M, Piddock L Paediatr Drugs. 2021; 23(5):465-484.

PMID: 34435316 PMC: 8418595. DOI: 10.1007/s40272-021-00465-z.


Metabolism, Excretion, and Pharmacokinetics of [ C]-Cefiderocol (S-649266), a Siderophore Cephalosporin, in Healthy Subjects Following Intravenous Administration.

Miyazaki S, Katsube T, Shen H, Tomek C, Narukawa Y J Clin Pharmacol. 2019; 59(7):958-967.

PMID: 30730562 PMC: 6593826. DOI: 10.1002/jcph.1386.


Prospective monitoring of cefepime in intensive care unit adult patients.

Chapuis T, Giannoni E, Majcherczyk P, Chiolero R, Schaller M, Berger M Crit Care. 2010; 14(2):R51.

PMID: 20359352 PMC: 2887166. DOI: 10.1186/cc8941.


Influence of E. coli lipopolysaccharide induced fever on the plasma kinetics of cefepime in cross-bred calves.

Pawar Y, Sharma S Vet Res Commun. 2007; 32(2):123-30.

PMID: 17610035 DOI: 10.1007/s11259-007-9010-1.